Tiempo para tamización universal de COVID-19 en la gestante. Reflexión desde la prevalencia del portador asintomático.

  • Milton César Gómez Pontificia Universidad Javeriana Cali https://orcid.org/0000-0001-6406-7229
  • Camila Pérez-Tellez Pontificia Universidad Javeriana Cali
Palabras clave: Covid-19, Embarazo, Coronavirus, SARS-CoV-2, Infección asintomática, Infección perinatal

Resumen

El presente artículo plantea la necesidad de considerar el  tamizaje universal para COVID-19 en el grupo de gestantes  a partir de las implicaciones históricas de anteriores pandemias y su relación con mayor morbimortalidad en el binomio materno fetal, así mismo la alta prevalencia de portadores asintomáticos y su alta capacidad de infectividad, la debilidad de los cribados a través de  encuestas y el hecho de ser grupo centinela en caso de otras epidemias e infecciones de interés de vigilancia en salud pública.

Abstract:

This article raises the need to consider universal screening for COVID-19 in the demographic of pregnant women based on the historical implications of previous pandemics and their relationship with greater morbidity and mortality in the maternal-fetal binomial, as well as the high prevalence of asymptomatic carriers and their high infectivity, the weakness of screening through surveys and the fact of being a sentinel group in the case of other epidemics and infections of interest for public health surveillance.

Key words: Covid-19, pregnancy, coronavirus, SARS-CoV-2, asymptomatic infections, perinatal infection.

 

Biografía del autor/a

Milton César Gómez, Pontificia Universidad Javeriana Cali

Médico, Especialista en Ginecología y Obstetricia, Magíster en Epidemiología, Fellow Colegio Americano de Ginecología y Obstetricia (FACOG), Director Postgrado Ginecología, Profesor Departamento Maternoinfantil.

Camila Pérez-Tellez, Pontificia Universidad Javeriana Cali

Médica

Citas

Poon LC, Yang H, Kapur A, Melamed N, Dao B, Divakar H et al. Global interim guid-ance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. Int J Gynecol Obstet. 2020; ijgo.13156. DOI: 10.1002/ijgo.13156

Gandhi M, Havlir D. The Time for Universal Masking of the Public for Coronavirus Dis-ease 2019 Is Now. Open Forum Infect Dis. 1 de abril de 2020;7(4):1-3. DOI: 10.1093/ofid/ofaa131

Rojas-Suarez J, Bello-Muñoz C, Paternina-Caicedo A, Bourjeily G, Carino G, Dueñas C. Maternal Mortality Secondary to Acute Respiratory Failure in Colombia: A Population-Based Analysis. Lung. 2015; 193(2):231-7. DOI: 10.1007/s00408-014-9677-3

Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M et al. Outcome of coro-navirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systemat-ic review and meta-analysis. Am J Obstet Gynecol MFM. 2020; 100107. DOI: 10.1016/j.ajogmf.2020.100107

Hosier H, Farhadian S, Morotti R, Deshmukh U, Lu-Culligan A, Campbell K et al. SARS-CoV-2 Infection of the Placenta [Internet]. Sexual and Reproductive Health. 2020. DOI: 10.1101/2020.04.30.20083907

Haby MM, Pinart M, Elias V, Reveiz L. Prevalence of asymptomatic Zika virus infection: a systematic review. Bull World Health Organ. 2018; 96(6):402-413D. DOI: 10.2471/BLT.17.201541

Weilg C, Troyes L, Villegas Z, Silva-Caso W, Mazulis F, Febres A et al. Detection of Zika virus infection among asymptomatic pregnant women in the North of Peru. BMC Res Notes. 2018; 11(1):311. DOI: 10.1186/s13104-018-3400z

Wilder-Smith A, Teleman MD, Heng BH, Earnest A, Ling AE, Leo YS. Asymptomatic SARS Coronavirus Infection among Healthcare Workers, Singapore. Emerg Infect Dis. 2005; 11(7):1142-5. DOI: 10.3201/eid1107.041165

Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020; 10. DOI: 10.2807/1560-7917.ES.2020.25.10.2000180

Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. Epidemiolo-gy; 2020. DOI: 10.1101/2020.04.14.20062463

Sutton D, Fuchs K, D’Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. 2020; NEJMc2009316. DOI: 10.1056/NEJMc2009316

Gostic K, Gomez AC, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effec-tiveness of symptom and risk screening to prevent the spread of COVID-19. eLife. 2020; 9:e55570.

Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymp-tomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 24 de abril de 2020;NEJMoa2008457. DOI: 10.1056/NEJMoa2008457

Cereda D, Tirani M, Rovida F, Demicheli V, Ajelli M, Poletti P et al. The early phase of the COVID-19 outbreak in Lombardy, Italy. ArXiv200309320 Q-Bio. 2020. Disponible en: http://arxiv.org/abs/2003.09320

Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Viro-logical assessment of hospitalized patients with COVID-2019. Nature. 2020. Disponible en: http://www.nature.com/articles/s41586-020-2196-x

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020; 382(12):1177-9. DOI: 10.1056/NEJMc2001737

Publicado
2021-06-23
Cómo citar
Gómez, M., & Pérez-Tellez, C. (2021). Tiempo para tamización universal de COVID-19 en la gestante. Reflexión desde la prevalencia del portador asintomático. Salutem Scientia Spiritus, 7(2), 64-67. Recuperado a partir de https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/2403